Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 444

  • Showing results for wedemeyer h. Search instead for Wedemyer H (1 item)
1.

Hepatitis E virus ORF 1 induces proliferative and functional T-cell responses in patients with ongoing and resolved hepatitis E.

Al-Ayoubi J, Behrendt P, Bremer B, Suneetha PV, Gisa A, Rinker F, Manns MP, Cornberg M, Wedemeyer H, Kraft ARM.

Liver Int. 2017 Jul 18. doi: 10.1111/liv.13521. [Epub ahead of print]

PMID:
28718943
2.

Grazoprevir, Ruzasvir, and Uprifosbuvir for HCV After NS5A Treatment Failure.

Wyles D, Wedemeyer H, Ben-Ari Z, Gane EJ, Hansen JB, Jacobson IM, Laursen AL, Luetkemeyer A, Nahass R, Pianko S, Zeuzem S, Jumes P, Huang HC, Butterton J, Robertson M, Wahl J, Barr E, Joeng HK, Martin E, Serfaty L; C-CREST Part C and C-SURGE Investigators.

Hepatology. 2017 Jul 7. doi: 10.1002/hep.29358. [Epub ahead of print]

PMID:
28688129
3.

Safety of the 2D/3D direct acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - a pooled analysis.

Poordad F, Nelson DR, Feld JJ, Fried MW, Wedemeyer H, Larsen L, Cohen DE, Cohen E, Mobashery N, Tatsch F, Foster GR.

J Hepatol. 2017 Jun 20. pii: S0168-8278(17)32083-4. doi: 10.1016/j.jhep.2017.06.011. [Epub ahead of print]

4.

Clinical course and core variability in HBV infected patients without detectable anti-HBc antibodies.

Anastasiou OE, Widera M, Verheyen J, Korth J, Gerken G, Helfritz FA, Canbay A, Wedemeyer H, Ciesek S.

J Clin Virol. 2017 Aug;93:46-52. doi: 10.1016/j.jcv.2017.06.001. Epub 2017 Jun 8.

PMID:
28622640
5.

Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients.

Phillips S, Mistry S, Riva A, Cooksley H, Hadzhiolova-Lebeau T, Plavova S, Katzarov K, Simonova M, Zeuzem S, Woffendin C, Chen PJ, Peng CY, Chang TT, Lueth S, De Knegt R, Choi MS, Wedemeyer H, Dao M, Kim CW, Chu HC, Wind-Rotolo M, Williams R, Cooney E, Chokshi S.

Front Immunol. 2017 May 29;8:621. doi: 10.3389/fimmu.2017.00621. eCollection 2017.

6.

[Hepatitis E - More than a Rare Travel-Associated Infectious Disease!]

Wedemeyer H.

Dtsch Med Wochenschr. 2017 Jun;142(11):833-837. doi: 10.1055/s-0043-106715. Epub 2017 May 31. German.

PMID:
28564737
7.

Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls.

Heidrich B, Vital M, Plumeier I, Döscher N, Kahl S, Kirschner J, Ziegert S, Solbach P, Lenzen H, Potthoff A, Manns MP, Wedemeyer H, Pieper DH.

Liver Int. 2017 May 31. doi: 10.1111/liv.13485. [Epub ahead of print]

PMID:
28561276
8.

Cytomegalovirus-Driven Adaptive-Like Natural Killer Cell Expansions Are Unaffected by Concurrent Chronic Hepatitis Virus Infections.

Malone DFG, Lunemann S, Hengst J, Ljunggren HG, Manns MP, Sandberg JK, Cornberg M, Wedemeyer H, Björkström NK.

Front Immunol. 2017 May 8;8:525. doi: 10.3389/fimmu.2017.00525. eCollection 2017.

9.

Seroprevalence of antibodies and antigens against hepatitis A-E viruses in refugees and asylum seekers in Germany in 2015.

Jablonka A, Solbach P, Wöbse M, Manns MP, Schmidt RE, Wedemeyer H, Cornberg M, Behrens GMN, Hardtke S.

Eur J Gastroenterol Hepatol. 2017 Aug;29(8):939-945. doi: 10.1097/MEG.0000000000000889.

PMID:
28492419
10.

Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis.

Wedemeyer H, Craxí A, Zuckerman E, Dieterich D, Flisiak R, Roberts SK, Pangerl A, Zhang Z, Martinez M, Bao Y, Calleja JL.

J Viral Hepat. 2017 May 8. doi: 10.1111/jvh.12722. [Epub ahead of print]

PMID:
28480525
11.

Reply to Letter to the Editor.

Wranke A, Wedemeyer H.

Curr Opin Virol. 2017 Apr;23:131. doi: 10.1016/j.coviro.2017.03.005. Epub 2017 Apr 29. No abstract available.

PMID:
28461142
12.

Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.

Polaris Observatory HCV Collaborators.

Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161-176. doi: 10.1016/S2468-1253(16)30181-9. Epub 2016 Dec 16.

PMID:
28404132
13.

Prevalence and genotype distribution of hepatitis delta virus among chronic hepatitis B carriers in Central Vietnam.

Nguyen HM, Sy BT, Trung NT, Hoan NX, Wedemeyer H, Velavan TP, Bock CT.

PLoS One. 2017 Apr 12;12(4):e0175304. doi: 10.1371/journal.pone.0175304. eCollection 2017.

14.

Low Risk of Developing Chronic Hepatitis E in Heart Transplant Recipients: A Prospective 2-Year Follow-Up Study.

Pischke S, Bara C, Behrendt P, Haverich A, Manns MP, Wedemeyer H.

Intervirology. 2016;59(5-6):254-255. doi: 10.1159/000464133. Epub 2017 Apr 13. No abstract available.

PMID:
28402973
15.

HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patients.

Rockstroh JK, Feld JJ, Chevaliez S, Cheng K, Wedemeyer H, Sarrazin C, Maasoumy B, Herman C, Hackett J Jr, Cohen DE, Dawson GJ, Cloherty G, Pawlotsky JM.

J Virol Methods. 2017 Jul;245:14-18. doi: 10.1016/j.jviromet.2017.03.002. Epub 2017 Mar 27.

16.

Home-based drainage of refractory ascites by a permanent-tunneled peritoneal catheter can safely replace large-volume paracentesis.

Solbach P, Höner Zu Siederdissen C, Taubert R, Ziegert S, Port K, Schneider A, Hueper K, Manns MP, Wedemeyer H, Jaeckel E.

Eur J Gastroenterol Hepatol. 2017 May;29(5):539-546. doi: 10.1097/MEG.0000000000000837.

PMID:
28350743
17.

Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry.

Welzel TM, Hinrichsen H, Sarrazin C, Buggisch P, Baumgarten A, Christensen S, Berg T, Mauss S, Teuber G, Stein K, Deterding K, van Bömmel F, Heyne R, John C, Zimmermann T, Lutz T, Schott E, Hettinger J, Kleine H, König B, Hüppe D, Wedemeyer H.

J Viral Hepat. 2017 Mar 25. doi: 10.1111/jvh.12708. [Epub ahead of print]

PMID:
28342229
18.

Long-term outcome of chronic hepatitis C virus infection in a real-world setting: The German LOTOS study.

Wedemeyer H, Reimer J, Sandow P, Hueppe D, Lutz T, Gruengreiff K, Goelz J, Christensen S, Pfeiffer-Vornkahl H, Alshuth U, Manns MP.

Liver Int. 2017 Mar 1. doi: 10.1111/liv.13399. [Epub ahead of print]

PMID:
28247572
19.

Clinical Impact of Liver Biopsies in Liver Transplant Recipients.

Voigtländer T, Alten TA, Kirstein MM, Lehner F, Manns MP, Schlué J, Wedemeyer H, Lankisch TO.

Ann Transplant. 2017 Feb 24;22:108-114.

20.

A screening assay for the identification of host cell requirements and antiviral targets for hepatitis D virus infection.

Buchmann B, Döhner K, Schirdewahn T, Sodeik B, Manns MP, Wedemeyer H, Ciesek S, von Hahn T.

Antiviral Res. 2017 May;141:116-123. doi: 10.1016/j.antiviral.2017.02.008. Epub 2017 Feb 20.

PMID:
28223128

Supplemental Content

Loading ...
Support Center